BioMarin Pharmaceutical Inc.

BMRN · NasdaqGS

Price$0.00+0.00 (+0.00%)

Price History

Volume & Moving Averages

Price50D200D

Analyst Price Target

$0.00▲ 0.0% above current price

Range: $0.00 – $0.00 · 0 analysts

Based on Wall Street analyst estimates — not a Stockinder prediction.

About the company

Jarvis is thinking

Key Metrics

Report card

Open as standalone page ↗

Jarvis is thinking

Recent Notable Coverage

Jarvis is thinking

Report Card

Growth

Health

Risk

Value

Quality

Ownership

Insider and institutional holdings, from Yahoo Finance — for Indian companies this roughly tracks promoter (insiders) and combined FII/DII (institutions) stakes, though not split out the same way a shareholding-pattern filing would.

Insiders0.3%

Institutions103.8%

Public / Other

Income Statement

	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31
Total money the company brought in from its core business during the period, before any costs are subtracted.	$3.22B	$2.85B	$2.42B	$2.10B	$1.85B	$1.86B	$1.70B	$1.49B	$1.31B	$1.12B
The direct costs of producing what was sold — raw materials, manufacturing, direct labor.	$717.44M	$580.24M	$514.85M	$483.67M	$470.51M	$524.27M	$359.47M	$315.26M	$241.79M	$209.62M
Profit from core operations after subtracting the cost of revenue and operating expenses like R&D and marketing, but before interest and taxes.	$409.48M	$484.21M	$158.10M	$149.56M	-$82.34M	-$36.77M	-$100.46M	-$123.52M	-$14.70M	-$803.43M
Operating income as a percentage of revenue.	12.7%	17.0%	6.5%	7.1%	-4.5%	-2.0%	-5.9%	-8.3%	-1.1%	-71.9%
The company's bottom-line profit after all expenses, interest, and taxes are subtracted.	$348.90M	$426.86M	$167.65M	$141.56M	-$64.08M	$859.10M	-$23.85M	-$77.21M	-$117.04M	-$630.21M
Net income divided by the number of shares outstanding — profit attributable to each share.	$1.82	$2.25	$0.89	$0.76	$-0.35	$4.75	$-0.13	$0.00	$0.00	$-3.00
Like basic EPS, but accounts for shares that could be created from stock options or convertible securities — a more conservative per-share profit figure.	$1.80	$2.21	$0.87	$0.75	$-0.35	$4.53	$-0.13	$0.00	$0.00	$-3.00

Balance Sheet

	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31
Cash and highly liquid short-term investments the company can access almost immediately.	$1.31B	$942.84M	$755.13M	$724.53M	$587.28M	$649.16M	$437.45M	$493.98M	$598.03M	$408.33M
Everything the company owns that has value — cash, property, inventory, investments, and more.	$7.59B	$6.99B	$6.84B	$6.38B	$6.00B	$5.85B	$4.69B	$4.43B	$4.63B	$4.02B
All of the company's interest-bearing borrowings, short and long term combined.	–	$0	$493.88M	–	–	$0	$361.88M	$0	$360.95M	$22.48M
Everything the company owes — debt, unpaid bills, and other obligations.	$1.51B	$1.33B	$1.89B	$1.77B	$1.73B	$1.74B	$1.57B	$1.46B	$1.82B	$1.26B
What would be left for shareholders if the company sold all its assets and paid off all its debts — total assets minus total liabilities.	$6.09B	$5.66B	$4.95B	$4.60B	$4.27B	$4.11B	$3.12B	$2.97B	$2.81B	$2.77B

Cash Flow Statement

	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31
Actual cash generated by the core business, as opposed to accounting profit, which can include non-cash items.	$827.99M	$572.84M	$159.26M	$175.90M	$304.54M	$85.36M	$48.26M	$20.21M	-$8.76M	-$227.84M
Cash spent on physical assets like property, equipment, and infrastructure to maintain or grow the business.	$103.04M	$85.42M	$96.69M	$120.96M	$95.58M	$114.31M	$145.03M	$144.62M	$199.22M	$148.38M
Cash left over after capital expenditures — money the company could use for dividends, buybacks, debt repayment, or reinvestment.	$724.96M	$487.42M	$62.57M	$54.94M	$208.96M	-$28.95M	-$96.76M	-$124.41M	-$207.98M	-$376.22M

	You	Peer avg
P/E	177.7	20.6
Revenue Growth	+19.9%	+56.8%
ROE	1.2%	-42.0%

BioMarin Pharmaceutical Inc.

Price History

Volume & Moving Averages

Analyst Price Target

About the company

Key Metrics

Report card

Jarvis Analysis

Recent Notable Coverage

Report Card

Ownership

Quick Actions

Reports & Coverage

Con Call Reports

Board of Directors / Annual Reports

Recent Articles

Income Statement

Balance Sheet

Cash Flow Statement

Peer Comparison